Respiratory tract infection is the number-one cause of communicable death worldwide. The World Health Organisation state that respiratory infections (such as pneumonia and tuberculosis-TB) are the overall third cause of death globally. To address this, the Respiratory Technology Team have been developing advanced inhaled medicines for lung infection. Micron-particles are being engineered that have sustained drug release when deposited at sites of infection or combine multiple therapies in one particle. It is established that infections such as TB are more responsive to multiple antibiotic therapies, however this is usually through oral or intravenous delivery. By combining advanced particle engineering with a firm knowledge of aerosol science we can target bacteria locally and ensure enhanced bactericidal effect with reduced side-effects and antibiotic resistance.